Uy Ear
Stock Analyst at Mizuho
(3.03)
# 1,078
Out of 4,667 analysts
56
Total ratings
34.38%
Success rate
5.02%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $27.63 | +44.77% | 5 | Nov 13, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $4.99 | +220.53% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $16.63 | +140.53% | 1 | May 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $145 → $179 | $109.93 | +62.83% | 5 | May 17, 2024 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $17 → $18 | $10.17 | +76.99% | 12 | May 15, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $25 → $21 | $15.83 | +32.66% | 10 | May 9, 2024 | |
| QURE uniQure | Maintains: Neutral | $7 → $6 | $5.69 | +5.54% | 3 | May 8, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $12.73 | +80.75% | 3 | Mar 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $116 → $140 | $124.08 | +12.83% | 10 | Feb 8, 2024 | |
| RVNC Revance Therapeutics | Maintains: Buy | $35 → $16 | $3.85 | +316.12% | 1 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $154.55 | -74.12% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.07 | +383.09% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.93 | +222.55% | 2 | Mar 1, 2023 |
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $27.63
Upside: +44.77%
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $4.99
Upside: +220.53%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $16.63
Upside: +140.53%
Sarepta Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $145 → $179
Current: $109.93
Upside: +62.83%
Arcutis Biotherapeutics
May 15, 2024
Maintains: Buy
Price Target: $17 → $18
Current: $10.17
Upside: +76.99%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Neutral
Price Target: $25 → $21
Current: $15.83
Upside: +32.66%
uniQure
May 8, 2024
Maintains: Neutral
Price Target: $7 → $6
Current: $5.69
Upside: +5.54%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $12.73
Upside: +80.75%
Neurocrine Biosciences
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $124.08
Upside: +12.83%
Revance Therapeutics
Nov 22, 2023
Maintains: Buy
Price Target: $35 → $16
Current: $3.85
Upside: +316.12%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $154.55
Upside: -74.12%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.07
Upside: +383.09%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.93
Upside: +222.55%